Arcutis Biotherapeutics, Inc. (ARQT)
| Market Cap | 1.60B |
| Revenue (ttm) | 212.82M |
| Net Income (ttm) | -129.72M |
| Shares Out | 119.20M |
| EPS (ttm) | -1.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,004,068 |
| Open | 13.61 |
| Previous Close | 13.82 |
| Day's Range | 13.06 - 13.61 |
| 52-Week Range | 7.86 - 17.75 |
| Beta | 1.77 |
| Analysts | Strong Buy |
| Price Target | 18.80 (+40.4%) |
| Earnings Date | Aug 13, 2025 |
About ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand ... [Read more]
Financial Performance
In 2024, Arcutis Biotherapeutics's revenue was $196.54 million, an increase of 229.74% compared to the previous year's $59.61 million. Losses were -$140.04 million, -46.58% less than in 2023.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ARQT stock is "Strong Buy." The 12-month stock price target is $18.8, which is an increase of 40.40% from the latest price.
News
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in i...
Arcutis Biotherapeutics: A Closer Look At The Atopic Dermatitis Direction
Arcutis Biotherapeutics' ZORYVE (roflumilast) offers superior efficacy and safety over current topical treatments for mild-to-moderate atopic dermatitis. The atopic dermatitis market is large and shif...
Arcutis' ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis
The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adults with mild to moderate atopic dermatitis (AD) Recommendation ...
Arcutis Biotherapeutics: Another Approval Under Their Belt
Shares of Arcutis Biotherapeutics have fallen by 5% since my March update. Zoryve's 4th approval in scalp & body psoriasis should further boost sales and contribute to the "portfolio effect". IP devel...
Arcutis: Out Of The Woods, Ready For Commercialization
Arcutis Biotherapeutics stands out in biotech for its impressive factor grades, which are rare in this sector. The recent FDA approval of ZORYVE Topical foam opens a significant revenue and profitabil...
Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
Four-week Phase 2 study to evaluate investigational, once-daily ZORYVE .05% in infants as young as 3 months to less than 2 years with atopic dermatitis Atopic dermatitis impacts 9.6 million children i...
Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference
New data from the Phase 3 INTEGUMENT-OLE long-term open label study show durable improvement in the signs and symptoms of atopic dermatitis (AD), including almost half of participants achieving no or ...
Arcutis Biotherapeutics: Navigating Commercialization With Promising Upside
Arcutis Biotherapeutics has de-risked significantly post-2023, with approvals, revenue growth and a clear path to cash flow breakeven by 2026. Recent financials show a temporary and insignificant reve...
Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
WESTLAKE VILLAGE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in im...
Arcutis' ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older
Once-daily ZORYVE foam provides powerful clearance and rapid itch relief from head to toe with no limitation on duration of use More than half of the nearly 9 million people in the United States with ...
New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice
Arcutis announced the publication of 14 consensus statements from the Genital Psoriasis Wellness Consortium on the impact of genital psoriasis on patients.
Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology
Once-daily, investigational ZORYVE foam 0.3%, rapidly improved psoriasis of the scalp and body, including itch, when used as a monotherapy 66.4% of individuals treated with ZORYVE foam achieved Scalp-...
Arcutis Biotherapeutics, Inc. (ARQT) Q1 2025 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Amanda Sheldon - Head of Corporate Communications Frank Watanabe - President a...
Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update
Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible reset...
Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets
Arcutis Biotherapeutics is rated a buy with a $19 price target, driven by strong Zoryve sales, a solid balance sheet, and strategic CFO transition. CFO David Topper is stepping down, replaced by Latha...
Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025
WESTLAKE VILLAGE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...
Arcutis Announces Chief Financial Officer Transition
WESTLAKE VILLAGE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...
Arcutis and Padagis Agree to Stay Patent Lawsuit
WESTLAKE VILLAGE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference
WESTLAKE VILLAGE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
As of March 25, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
Data demonstrated favorable safety and local tolerability of ZORYVE® (roflumilast) cream 0.15% in adults and children with atopic dermatitis (AD) with prior inadequate response, intolerance, and contr...
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting
One poster will share pooled INTEGUMENT data of ZORYVE® (roflumilast) cream 0.15% in atopic dermatitis (AD) in patients with prior inadequate response, intolerance, and/or contraindications to topical...
Arcutis: ZORYVE Net Product Revenue Growth Isn't The Only Opportunity On Deck
Data from phase 1b study, using ARQ-255 for the treatment of patients with alopecia areata, expected in the 1st half of 2025. The global alopecia areata market size is expected to be worth $6.92 billi...
Arcutis Biotherapeutics: Reiterating Strong Buy As Q4 Results Top Expectations
Arcutis Biotherapeutics is a strong buy due to ZORYVE's rapid sales growth and potential for positive earnings within 12 months. ZORYVE, a non-steroidal cream for psoriasis and dermatitis, saw Q4 sale...
U.S. FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of October 13, 2025 Application supported by positive efficacy and safety data from pivotal...